Xia Y. Working together to advance cardio-oncology in China. JACC Cardio Oncol. 2020;2:144–5.

Article  Google Scholar 

• Ng CT. Advancing Cardio-Oncology in Asia. Korean Circ J. 2023;53:69–91. This research paper is important because it highlights the importance of cardio-oncology in Asia and the need for further research and collaboration to improve the care of cancer patients with cardiovascular complications.

Article  PubMed  Google Scholar 

Liu Y. Emergence, development, and future of cardio-oncology in emergence, development, and future of cardio-oncology in China. Chin Med J (Engl). 2018;131:2640–4.

Article  PubMed  PubMed Central  Google Scholar 

Xia Y, Liu J. Cardio-oncology. 4th ed. China Cardio-Oncology Association. 2018

Xia C. Cancer statistics in China and United States, 2022: profiles, and determinants. Chin Med J (Eng). 2022;135:584–90.

Article  Google Scholar 

Zhang Y. Cardio-oncology in China: we are on the go! JACC CardioOncol. 2020;2:139–43.

Article  PubMed  PubMed Central  Google Scholar 

Lv H, Xia Y. Summary and Prospect. In: Xia Y, Liu J, editors. Manual of cardio-oncological therapeutics. China: People’s Health Publishing House; 2019. p. 295–8.

Google Scholar 

Li Y. Factors associated with outpatient satisfaction in tertiary hospitals in china: a systematic review. Int J Environ Res Public Health. 2020;17:7070–99.

Article  PubMed  PubMed Central  Google Scholar 

Shen X. Analysis of the impact of China’s hierarchical medical system and online appointment diagnosis system on the sustainable development of public health: a case study of Shanghai. Sustainability. 2019;11:6564–90.

Article  Google Scholar 

Zhi L. Running an Internet hospital in China: perspective based on a case study. J Med Internet Res. 2021;23:1–9.

Article  Google Scholar 

Zheng JC. Medical education reform in china: the Shanghai medical training model. J Grad Med Educ. 2020;12:655–60.

Article  PubMed  PubMed Central  Google Scholar 

Gillebert TC. ESC core curriculum for the general cardiologist (2013). Eur Heart J. 2013;34:2381–411.

Article  PubMed  Google Scholar 

•• Tse G. The potential impact of the 2022 ESC Cardio-Oncology Guidelines on Clinical Practice in China. JACC CardioOncol. 2023;5:153–5. This paper is very important because it highlights the need for standardised guidelines for the management of cardio-oncology patients in China, and how the ESC guidelines can help to fill this gap. The paper also provides insights into the potential impact of the ESC guidelines on clinical practice in China and how they can help to improve the care of cancer patients with cardiovascular complications.

Article  PubMed  PubMed Central  Google Scholar 

Avila MS. Carvedilol for prevention of chemotherapy-related cardiotoxicity The CECCY Trial. JACC CardioOncol. 2018;71:2281–90.

Article  CAS  Google Scholar 

Young AM. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018;36:2017–23.

Article  CAS  PubMed  Google Scholar 

Chan JSK. Cardiovascular outcomes and hospitalizations in Asian patients receiving immune checkpoint inhibitors: a population-based study. Curr Probl Cardiol. 2023;48:1–14.

Article  Google Scholar 

Zhang Z. Chinese expert consensus on the surveillance and management of immune checkpoint inhibitor-related myocarditis (2020 version). Chin J Clin Oncol. 2020;47:1027–38.

Google Scholar 

•• Lyon AR. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International cardio-oncology Society (IC-OS). Eur Heart J. 2022;43:4229–361. This paper holds significant importance as it offers updated and comprehensive guidelines for the management of cardiovascular health in cancer patients, addressing the emerging field of cardio-oncology. The collaboration between esteemed organizations such as the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO), and the International Cardio-Oncology Society (IC-OS) also ensures that the guidelines are based on the latest scientific evidence and expert consensus. Lastly, its publication in the prestigious European Heart Journal grants it wide visibility and influence in the medical community, thereby fostering improved patient care and outcomes.

Article  PubMed  Google Scholar 

• Hu H. Global trade pattern of medical devices and China’s trade position: based on data from 2001–2020. Front Public Health. 2022;10:1–10. The paper is important as it highlights the significant growth of China’s medical device industry over the past two decades and its increasing role in the global market. The findings of this study are important for policy makers and stakeholders in the medical device industry, as they provide insights into the changing dynamics of the global market and the opportunities and challenges for different players in this industry.

Google Scholar 

Jakovlijevic M. Asian innovation in pharmaceutical and medical device industry - beyond tomorrow. J Med Econ. 2021;24:42–50.

Article  Google Scholar 

• Liu D. Quality control of next-generation sequencing-based In vitro diagnostic test for onco-relevant mutations using multiplex reference materials in plasma. J Cancer. 2018;18:1680–8. Importance of article can be emphasized because it emphasizes the collaborative evaluation of multiple NGS platforms using reference materials provides valuable insights for improving the performance and accuracy of NGS-based cancer in vitro diagnostics.

Article  Google Scholar 

Wang GN. Consensus on anesthetic management of patients with cancer having heart disease after neoadjuvant chemotherapy in China (2021 version). Chin J Clin Oncol. 2022;49:757–63.

Google Scholar 

Sadler D. Cardio oncology: digital innovations, precision medicine and health equity. Front Cardiovasc Med. 2022;9:1–9.

Article  Google Scholar 

•• Lin H. Using big data to improve cardiovascular care and outcomes in China: a protocol for the CHinese Electronic health Records Research in Yinzhou (CHERRY) Study. BMJ Open. 2018;8:1–11. This paper is significantly important because it presents a protocol for a large-scale study that aims to use big data to improve cardiovascular care and outcomes in China, where cardiovascular disease is a major public health challenge. The study demonstrates the potential of big data to transform healthcare delivery and improve health outcomes in resource-limited settings.

Article  Google Scholar 

Zhang Y. Applications and challenges of health insurance databases in the field of cardio-oncology. Chin J Pharmacoepidemiol. 2022;31:271–9.

Google Scholar 

Wang CH. Epidemiological survey of outpatients from cardio-oncology multidisciplinary ambulatory service based on single clinical center. Chin J Clin Med. 2021;28:172–6.

Google Scholar 

•• Lv XF. Role and molecular mechanism of traditional Chinese medicine in preventing cardiotoxicity associated with chemoradiotherapy. Front Cardiovasc Med. 2022;9:1–18. This paper is important as Traditional Chinese medicine (TCM) has been used for centuries to treat various health issues and has gained attention as a complementary therapy for cancer treatment. The paper also provides insights into the molecular mechanisms of TCM in preventing cardiotoxicity associated with chemoradiotherapy, contributing to the growing body of research on TCM’s potential benefits for cancer patients. The findings of this paper could potentially lead to new treatment options that combine traditional cancer treatments with TCM, improving overall treatment outcomes and reducing the risk of cardiotoxicity.

Article  Google Scholar 

Jiang Y. Effect of traditional Chinese medicine on the cardiovascular diseases. Front Pharmacol. 2022;13:1–14.

Google Scholar 

Wen HN. Precision cardio-oncology: use of mechanistic pharmacokinetic and pharmacodynamic modeling to predict cardiotoxicities of anti-cancer drugs. Front Oncol. 2022;11:1–9.

Article  Google Scholar 

Sadler D. Practical and cost-effective model to build and sustain a cardio-oncology program. Cardiooncology. 2020;6(9):1–10.

Google Scholar 

Chen H. Artificial intelligence applications in cardio-oncology: leveraging high dimensional cardiovascular data. Front Cardiovasc Med. 2022;9:1–7

Martinez DS. Artificial intelligence opportunities in cardio-oncology: overview with spotlight on electrocardiography. Am Heart J Plus. 2022;15:1–32.

Google Scholar 

•• Kwan JM. The role and impact of social media in cardio-oncology during the COVID-19 pandemic. Curr Oncol Rep. 2021;23:1–19. The paper is extremely important as it highlights the significance of social media in cardio-oncology during the COVID-19 pandemic. It emphasises the potential of social media in advancing patient care and enhancing remote communication between healthcare providers and patients. The paper also underscores the importance of collaboration and knowledge-sharing among healthcare professionals and patients to improve treatment outcomes. It contributes to the growing body of literature on cardio-oncology and provides valuable insights into the use of social media in healthcare. The paper is relevant and timely, given the current healthcare landscape.

Article  Google Scholar 

Wang XG. Advances and challenges in pediatric cardio-oncology. Mol Cardiol China. 2020;20:3587–92.

Google Scholar